3020 Stock Overview
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Hefei Lifeon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.96 |
| 52 Week High | CN¥44.66 |
| 52 Week Low | CN¥16.49 |
| Beta | 0.17 |
| 1 Month Change | 2.33% |
| 3 Month Change | -5.39% |
| 1 Year Change | -40.91% |
| 3 Year Change | -20.68% |
| 5 Year Change | n/a |
| Change since IPO | 11.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3020 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 13.7% | 3.3% | -0.3% |
| 1Y | -40.9% | -14.4% | -14.6% |
Return vs Industry: 003020 underperformed the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 003020 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
| 3020 volatility | |
|---|---|
| 3020 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 003020 has not had significant price volatility in the past 3 months.
Volatility Over Time: 003020's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,219 | Xiaojuan Deng | www.lifeonapi.com |
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients. It operates through Pharmaceutical Industry, Pharmaceutical Wholesale and Distribution, and Pharmaceutical Retail Business segments. The company offers active pharmaceutical ingredients, which include nifedipine, paliperidone, prilocaine, methylphenidate hydrochloride, dimercaptosuccinic acid, doxazosin mesylate, paeonol, urea, felodipine, and troxerutin; and medical preparations, such as osmotic pump preparations, central nervous systems, Chinese patent medicines, eye drops, external use, and general oral medicines.
Hefei Lifeon Pharmaceutical Co., Ltd. Fundamentals Summary
| 3020 fundamental statistics | |
|---|---|
| Market cap | CN¥3.51b |
| Earnings (TTM) | CN¥226.67m |
| Revenue (TTM) | CN¥1.90b |
15.5x
P/E Ratio1.8x
P/S RatioIs 3020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3020 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.90b |
| Cost of Revenue | CN¥922.20m |
| Gross Profit | CN¥978.59m |
| Other Expenses | CN¥751.91m |
| Earnings | CN¥226.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 51.48% |
| Net Profit Margin | 11.93% |
| Debt/Equity Ratio | 1.9% |
How did 3020 perform over the long term?
See historical performance and comparison